Industry Overview - The 44th JPMorgan Healthcare Conference is taking place in San Francisco, attracting over 8,000 industry elites from biotechnology, pharmaceuticals, and medical devices [1][24] - The global pharmaceutical sector saw a record 516 licensing deals in the past year, totaling over $250.2 billion, indicating a rise in industry transaction activity [24] - The shadow of the "patent cliff" continues to loom over many large pharmaceutical companies, prompting them to actively seek targets and plan for the future [24] AI Integration - AI has transitioned from a concept to a core component of research and development, with companies increasingly focusing on its strategic importance [24][29] - AstraZeneca has elevated AI to a strategic level, implementing its AI Development Agent (AIDA) system to reduce CMC development time by 50% [29] - Eli Lilly announced a partnership with NVIDIA to establish an AI innovation lab, investing $1 billion over five years to accelerate drug development [7][32] AstraZeneca's Strategy - AstraZeneca is focusing on "next-generation dual antibodies + high-value ADCs" as pillars for innovation and growth, aiming for $80 billion in total revenue by 2030 [2][25] - The company has initiated 14 Phase III trials for its PD-1/TIGIT and PD-1/CTLA-4 dual antibodies, with peak sales expected to exceed $3 billion and $2 billion, respectively [5][28] - AstraZeneca's revenue grew by 11% in the first nine months of 2025, with core EPS increasing by 15% [6][29] Pfizer's Focus - Pfizer's strategy for 2026 emphasizes maximizing acquisition asset value, achieving key R&D milestones, and applying AI across its operations [9][33] - The company has reduced operational costs by $5.6 billion to offset declining COVID-19 revenue, which is projected to drop from $11 billion in 2024 to $6.5 billion in 2025 [11][35] - Pfizer is building a differentiated portfolio in the obesity market, aiming to launch products by 2028 that could tap into a market projected to reach $150 billion by 2030 [12][35] Novartis' Pipeline - Novartis is focusing on cardiovascular, renal, metabolic, immunology, neuroscience, and oncology, with a robust pipeline supported by various technology platforms [36][39] - The company expects nine products to achieve peak sales of over $1 billion, with CDK4/6 inhibitors potentially exceeding $10 billion in peak sales [39] - Novartis anticipates a compound annual growth rate of 5-6% in sales from 2025 to 2030 [39] Bristol-Myers Squibb's Approach - Bristol-Myers Squibb is diversifying its pipeline to navigate the patent cliff, focusing on neuroscience, cardiovascular, immunology, and oncology [16][40] - The company plans to disclose core registration data for 13 new molecular entities in 2026 and complete 14 Phase III trials [41] Sanofi's Business Development - Sanofi is actively pursuing business development to enhance its early pipeline, aiming to launch 8-12 high-quality early projects by 2028-2030 [22][49] - The company has completed over 20 business development transactions since 2025, including significant acquisitions to bolster its pipeline [49]

Investment Rating - The report maintains a "Buy" rating for the overseas education sector, particularly highlighting New Oriental as a key player [10]. Core Insights - The overseas education sector is experiencing improved operational efficiency and accelerated profit margin expansion, with New Oriental expected to report a revenue of $1.165 billion for Q2 FY26, representing a year-on-year growth of 12.2% [5][10]. - The report anticipates a significant increase in non-GAAP net profit for New Oriental, projected at $63 million, which is a 77.8% increase year-on-year, with a non-GAAP net profit margin of 5.4%, expanding by 2 percentage points [5][10]. Summary by Sections 1. Overseas Education - **Market Review**: The education index rose by 2.8% in the week of December 19-25, outperforming the Hang Seng Index by 1.8 percentage points, with a year-to-date increase of 13.1% [4]. - **Company Update**: New Oriental's revenue is expected to reach $1.165 billion, with the education business (including cultural tourism) contributing $957 million, a growth of 11% year-on-year [5][10]. - **Study Abroad Business**: The revenue from study abroad exam training and consulting is projected to decline by 3% to $242 million, reflecting a slowdown in growth due to high base effects from the previous year [2][5]. - **New Business Growth**: New business segments, including K9 competency training and learning machine services, are expected to grow by 21% to $364 million, driven by differentiated offerings for primary and secondary education [3][6]. - **Operating Profit Margin Improvement**: Despite a slowdown in high-margin study abroad business, the increase in competency business margins is expected to offset this. The non-GAAP operating profit margin is projected to expand by approximately 2 percentage points to 4.7% [6][10]. 2. Overseas Pharmaceuticals - **Market Review**: The Hang Seng Healthcare Index saw a slight increase of 0.02%, underperforming the Hang Seng Index by 1.24 percentage points [12]. - **Key Events**: Notable transactions include Sanofi's $2.2 billion acquisition of vaccine company Dynavax, which has a marketed hepatitis B vaccine and a promising shingles vaccine candidate [14]. - **Investment Recommendations**: The report suggests focusing on innovative drug companies with active business development opportunities and clinical progress in key pipelines, including companies like BeiGene and Innovent Biologics [15]. 3. Overseas Social Services - **Ctrip's Q3 Performance**: Ctrip reported a 16% year-on-year revenue increase to $18.4 billion, with strong performance across various business segments, particularly in international OTA platforms [17]. - **Tongcheng Travel's Q3 Performance**: Tongcheng Travel's revenue grew by 10% to $5.5 billion, with a notable increase in accommodation and core OTA business revenues [18]. - **Key Focus**: The report highlights potential growth in the outbound travel sector and the importance of hotel management services as additional growth drivers [19].

Core Viewpoint - AstraZeneca has submitted an application for the approval of gefurulimab in China, targeting generalized myasthenia gravis (gMG) as its indication, based on clinical trial progress [1] Group 1: Product Information - Gefurulimab is a mini bispecific antibody (25kD) that includes a variable region of the antibody heavy chain targeting C5 and an antibody fragment that specifically binds to albumin [1] - The smaller molecular weight of gefurulimab allows for better permeability, and its binding to albumin extends its half-life [1] Group 2: Disease Context - Generalized myasthenia gravis (gMG) is a rare, debilitating, chronic autoimmune neuromuscular disease that leads to muscle function loss and severe weakness [2] - Initial symptoms of gMG may include slurred speech, diplopia, ptosis, and weakness, with progression leading to more severe symptoms such as extreme fatigue, difficulty swallowing, choking, and respiratory failure [2]